Uracil

尿嘧啶

Report date: 2024/11/29 16:57:22

Base Information

Drug NameUracil
Drug Alias NameXyfid
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydropyrimidine dehydrogenase inhibitors
TargetsDihydropyrimidine dehydrogenase
Therapy Area/IndicationsHand-Foot SyndromeBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesVioquestAsymmetric TherapeuticsCahaba Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAnhui New Medicine Research InstituteNanometics (D.B.A. Phd Biosciences)
Active IndicationsN/A
Inactive IndicationsHand-Foot SyndromeBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksKEGG